{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:12:28Z","timestamp":1780445548424,"version":"3.54.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ejpb.2024.114522","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T07:24:52Z","timestamp":1728026692000},"page":"114522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Acoustic resonance technology and quality by design approach facilitate the development of the robust tetrandrine nano-delivery system"],"prefix":"10.1016","volume":"204","author":[{"given":"Xiaoyang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlu","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7961-7975","authenticated-orcid":false,"given":"Wenlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2017","key":"10.1016\/j.ejpb.2024.114522_b0005","first-page":"422","article-title":"Tetrandrine has anti-adipogenic effect on 3T3-L1 preadipocytes through the reduced expression and\/or phosphorylation levels of C\/EBP-\u03b1, PPAR-\u03b3, FAS, perilipin A, and STAT-3 (vol 476, pg 481","volume":"494","author":"Jang","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejpb.2024.114522_b0010","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202400274","article-title":"Advances in nano-preparations for improving tetrandrine solubility and bioavailability","author":"Ling","year":"2024","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ejpb.2024.114522_b0015","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/slct.201803592","article-title":"Design and Synthesis of Tetrandrine Derivatives as Potential Anti-tumor Agents Against A549 Cell Lines","volume":"4","author":"Niu","year":"2019","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.ejpb.2024.114522_b0020","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s10787-024-01452-9","article-title":"Therapeutic effects of tetrandrine in inflammatory diseases: a comprehensive review","volume":"32","author":"Song","year":"2024","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.ejpb.2024.114522_b0025","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2147\/IJN.S431599","article-title":"Preparation, Characterization, and Anti-Lung Cancer Activity of Tetrandrine-Loaded Stealth Liposomes","volume":"19","author":"Fang","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2024.114522_b0030","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1142\/S0192415X23500222","article-title":"Tetrandrine Inhibits Cancer Stem Cell Characteristics and Epithelial to Mesenchymal Transition in Triple-Negative Breast Cancer via SOD1\/ROS Signaling Pathway","volume":"51","author":"Liu","year":"2023","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.ejpb.2024.114522_b0035","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1111\/jphp.13339","article-title":"Tetrandrine: a review of its anticancer potentials, clinical settings, pharmacokinetics and drug delivery systems","volume":"72","author":"Luan","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2024.114522_b0040","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1002\/jcp.27470","article-title":"Tetrandrine, a novel inhibitor of ether-a-go-go-1 (Eag1), targeted to cervical cancer development","volume":"234","author":"Wang","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejpb.2024.114522_b0045","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1021\/acs.molpharmaceut.0c00026","article-title":"Inhalation of Tetrandrine-hydroxypropyl-\u03b2-cyclodextrin Inclusion Complexes for Pulmonary Fibrosis Treatment","volume":"17","author":"Su","year":"2020","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2024.114522_b0050","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0928-0987(94)00078-E","article-title":"Preparation and in vitro evaluation of tetrandrine-entrapped albumin microspheres as an inhaled drug delivery system","volume":"3","author":"Zeng","year":"1995","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114522_b0055","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/02652048.2020.1761905","article-title":"Preparation and characterisation of tetrandrine nanosuspensions and in vitro estimate antitumour activity on A549 lung cancer cell line","volume":"37","author":"Guo","year":"2020","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejpb.2024.114522_b0060","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1208\/s12249-011-9665-3","article-title":"Preparation, Characterization, Pharmacokinetics and Tissue Distribution of Solid Lipid Nanoparticles Loaded with Tetrandrine","volume":"12","author":"Li","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2024.114522_b0065","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1021\/mp500637b","article-title":"Coencapsulated Doxorubicin and Bromotetrandrine Lipid Nanoemulsions in Reversing Multidrug Resistance in Breast Cancer in Vitro and in Vivo","volume":"12","author":"Cao","year":"2015","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2024.114522_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120983","article-title":"Sub-50 nm ultra-small organic drug nanosuspension prepared by cavi-precipitation and its brain targeting potential","volume":"607","author":"Sinha","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114522_b0075","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1080\/17425247.2022.2110579","article-title":"Nanocrystals for controlled delivery: state of the art and approved drug products","volume":"19","author":"Kalhapure","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114522_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2019.101486","article-title":"Design space approach in the development of esculetin nanocrystals by a small-scale wet-bead milling process","volume":"55","author":"Zuo","year":"2020","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.ejpb.2024.114522_b0085","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijpharm.2014.05.003","article-title":"A new and improved method for the preparation of drug nanosuspension formulations using acoustic mixing technology","volume":"473","author":"Leung","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114522_b0090","doi-asserted-by":"crossref","first-page":"10653","DOI":"10.1021\/acs.jpcc.1c01300","article-title":"Resonant Acoustic Mixing Method to Produce Lipid-Based Liquid-Crystal Nanoparticles","volume":"125","author":"Yalcin","year":"2021","journal-title":"J. Phys. Chem. C"},{"key":"10.1016\/j.ejpb.2024.114522_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122287","article-title":"Pazopanib-laden lipid based nanovesicular delivery with augmented oral bioavailability and therapeutic efficacy against non-small cell lung cancer","volume":"628","author":"Nadaf","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114522_b0100","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejpb.2022.09.022","article-title":"DoE-based development of celecoxib loaded PLGA nanoparticles: In ovo assessment of its antiangiogenic effect","author":"Alonso-Gonz\u00e1lez","year":"2022","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics 180"},{"key":"10.1016\/j.ejpb.2024.114522_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2021.103066","article-title":"Formulation and optimization of cilnidipine loaded nanosuspension for the enhancement of solubility, dissolution and bioavailability","volume":"69","author":"Shaikh","year":"2022","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.ejpb.2024.114522_b0110","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijpharm.2017.07.047","article-title":"Dual centrifugation \u2013 A new technique for nanomilling of poorly soluble drugs and formulation screening by an DoE-approach","volume":"530","author":"Hagedorn","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114522_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2021.102559","article-title":"Development, optimization and in-vivo evaluation of cyanocobalamin loaded orodispersible films using hot-melt extrusion technology: A quality by design (QbD) approach","volume":"63","author":"Suryawanshi","year":"2021","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.ejpb.2024.114522_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123920","article-title":"A quality-by-design strategic approach for the development of bedaquiline-pretomanid nanoparticles as inhalable dry powders for TB treatment","volume":"653","author":"Patil","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114522_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2019.101208","article-title":"Development and evaluation of synchronized and sustained release Tripergium Wilfordii tablets based hot-melt extrusion and direct powder compression","volume":"53","author":"Tang","year":"2019","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.ejpb.2024.114522_b0130","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1080\/03639045.2022.2061988","article-title":"Exploring the influence factors and improvement strategies of drug polymorphic transformation combined kinetic and thermodynamic perspectives during the formation of nanosuspensions","volume":"47","author":"Meng","year":"2021","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2024.114522_b0135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejpb.2022.08.012","article-title":"Elucidating the particle size effect of andrographolide suspensions on their IVIVC performance in oral absorption","volume":"179","author":"Yao","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114522_b0140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijpharm.2017.12.028","article-title":"Nano-scale and molecular-level understanding of wet-milled indomethacin\/poloxamer 407 nanosuspension with TEM, suspended-state NMR, and Raman measurements","volume":"537","author":"Kuroiwa","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114522_b0145","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijpharm.2018.02.011","article-title":"Optimization of formulation and process parameters for the production of carvedilol nanosuspension by wet media milling","volume":"540","author":"Medarevi\u0107","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114522_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122428","article-title":"Highly water-soluble dapsone nanocrystals: Towards innovative preparations for an undermined drug","volume":"630","author":"Paredes Da Rocha","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114522_b0155","article-title":"Risk assessment and QbD based optimization of an Eprosartan mesylate nanosuspension: In-vitro characterization","volume":"567","author":"Shekhawat","year":"2019","journal-title":"PAMPA and in-Vivo Assessment, International Journal of Pharmaceutics"},{"key":"10.1016\/j.ejpb.2024.114522_b0160","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ijpharm.2019.01.054","article-title":"Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology","volume":"559","author":"Gajera","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114522_b0165","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3390\/ph16070943","article-title":"Pharmacokinetics of Curcumin Delivered by Nanoparticles and the Relationship with Antitumor Efficacy: A Systematic Review","volume":"16","author":"Silvestre","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejpb.2024.114522_b0170","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.3390\/pharmaceutics14061196","article-title":"siRNA Targeting Mcl-1 Potentiates the Anticancer Activity of Andrographolide Nanosuspensions via Apoptosis in Breast Cancer Cells","volume":"14","author":"Pengnam","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2024.114522_b0175","first-page":"455","article-title":"Safety of nanosuspensions in drug delivery, Nanomedicine: Nanotechnology","volume":"13","author":"Wang","year":"2017","journal-title":"Biology and Medicine"},{"key":"10.1016\/j.ejpb.2024.114522_b0180","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.phymed.2017.12.021","article-title":"Fabrication of surfactant-stabilized nanosuspension of naringenin to surpass its poor physiochemical properties and low oral bioavailability","volume":"40","author":"Singh","year":"2018","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejpb.2024.114522_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106123","article-title":"A new nanosuspension prepared with wet milling method for oral delivery of highly variable drug Cyclosporine A: development, optimization and in vivo evaluation","volume":"171","author":"Pinar","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114522_b0190","first-page":"2151","article-title":"Quality-by-design of nanopharmaceuticals - a state of the art, Nanomed.-Nanotechnol","volume":"13","author":"Bastogne","year":"2017","journal-title":"Biol. Med."},{"key":"10.1016\/j.ejpb.2024.114522_b0195","article-title":"Is it advantageous to use quality by design (QbD) to develop nanoparticle-based dosage forms for parenteral drug administration?","volume":"657","author":"Vieira","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114522_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121594","article-title":"Design and optimization of pH-sensitive Eudragit nanoparticles for improved oral delivery of triclabendazole","volume":"617","author":"Andr\u00e9s Real","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114522_b0205","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejpb.2022.10.018","article-title":"Design and optimization of metformin-loaded solid lipid nanoparticles for neuroprotective effects in a rat model of diffuse traumatic brain injury: A biochemical, behavioral, and histological study","volume":"181","author":"Ebrahimi","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114522_b0210","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.2174\/1381612824666180515125247","article-title":"Pharmaceutical Strategies for Stabilizing Drug Nanocrystals","volume":"24","author":"Yang","year":"2018","journal-title":"Curr. Pharm. Design"},{"key":"10.1016\/j.ejpb.2024.114522_b0215","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejps.2017.03.017","article-title":"A novel nanosuspension of andrographolide: Preparation, characterization and passive liver target evaluation in rats","volume":"104","author":"Guo","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114522_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123877","article-title":"Inhalable paclitaxel nanoagglomerate dry powders for lung cancer chemotherapy: Design of experiments-guided development, characterization and in vitro evaluation","volume":"653","author":"Chan","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114522_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2022.103528","article-title":"Freeze-drying of drug nanosuspension\u2013 study of formulation and processing factors for the optimization and characterization of redispersible cilostazol nanocrystals","volume":"74","author":"Jakubowska","year":"2022","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.ejpb.2024.114522_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119406","article-title":"Tea saponins as natural stabilizers for the production of hesperidin nanosuspensions","volume":"583","author":"Long","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114522_b0235","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijpharm.2011.12.024","article-title":"Quality by design approach for formulation development: A case study of dispersible tablets","volume":"423","author":"Charoo","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114522_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2022.112678","article-title":"Improving the oral delivery of benznidazole nanoparticles by optimizing the formulation parameters through a design of experiment and optimization strategy","volume":"217","author":"Arrua","year":"2022","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejpb.2024.114522_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122717","article-title":"Optimization of the different phases of the freeze-drying process of solid lipid nanoparticles using experimental designs","volume":"635","author":"Elbrink","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114522_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123879","article-title":"Oral delivery of posaconazole-loaded phospholipid-based nanoformulation: Preparation and optimization using design of experiments, machine learning, and TOPSIS","volume":"653","author":"Bayat","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114522_b0255","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2147\/IJN.S446895","article-title":"Sequentially Released Liposomes Enhance Anti-Liver Cancer Efficacy of Tetrandrine and Celastrol-Loaded Coix Seed Oil","volume":"19","author":"Chen","year":"2024","journal-title":"IJN"},{"key":"10.1016\/j.ejpb.2024.114522_b0260","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1021\/acs.jmedchem.1c01687","article-title":"Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery","volume":"65","author":"Wuelfing","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2024.114522_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2022.103503","article-title":"Development and evaluation of nanocrystals loaded hydrogel for topical application","volume":"74","author":"Kumar","year":"2022","journal-title":"J. Drug Delivery Sci. Technol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124003485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124003485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T19:08:49Z","timestamp":1729710529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641124003485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":53,"alternative-id":["S0939641124003485"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114522","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acoustic resonance technology and quality by design approach facilitate the development of the robust tetrandrine nano-delivery system","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114522","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114522"}}